ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine policy ecology

bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Alternative Medicines
The Scientist | Jul 1, 2012 | 10+ min read
As nonconventional medical treatments become increasingly mainstream, we take a look at the science behind some of the most popular.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Weathering Hantavirus: Ecological Monitoring Provides Predictive Model
Steve Bunk | Jul 4, 1999 | 7 min read
Photo: Steve Bunk Dave Tinnin, field research associate in the University of New Mexico's biology department, takes blood samples and measurements of rodents caught on the research station grounds. At the end of a freeway exit near Soccoro, N.M., the hairpin turn onto a gravel road is marked by a sign that warns, "Wrong Way." But it isn't the wrong way if you want to reach the University of New Mexico's (UNM) long-term ecological research (LTER) station. The sign's subterfuge is the first indi
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Predicting Future Zoonotic Disease Outbreaks
Ashley Yeager | Jun 1, 2018 | 10+ min read
A step-by-step study of diseases that jump species gives subtle clues about future epidemics.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Letters
The Scientist Staff | Aug 1, 2006 | 5 min read
Restoring natural capital As scientists and practitioners committed to ecological restoration, we found the analogy you made in your April issue1 between restoring natural capital (RNC)2 and new forms of cancer treatment3 to be an extremely powerful one. To a certain degree, RNC and ecological restoration in general, are indeed related to ecosystem degradation in the way that tumor ecology-based treatments are related to traditional cancer therapies, e.g., combined

Run a Search

ADVERTISEMENT